Qol-14. Health-Related Quality Of Life And Cognitive Functioning In Survivors Of Oligodendroglioma: An International Cross-Sectional Investigation
Florien Boele,Se Frances,Amelie Darlix,Francois Ducray,Emeline Tabouret,Michael Burger,Isabelle Ryden,Annika Malmstrom,Elodie Vauleon,Tomas Kazda,Mirjam Renovanz,Jan-Michael Werner,Liam Welsh,Paul Sanghera,Caroline Dehais,Isacco Desideri,Catherine McBain,Shaveta Mehta,Hannah Lord,Rajesh Jena,Karen Foweraker,Keyoumars Ashkan,Julien Engelhardt,Veronique Bourg,Ulrich Herrlinger,Aaron Lawson McLean,Caroline Hertler,Lene Haldbo-Classen,Rikke Dahlrot,Georges Noel,Xavier Durando,Ioana Hrab,Evangelia Razis,Aida Muhic,Martin Klein
DOI: https://doi.org/10.1093/neuonc/noae165.1049
2024-11-29
Neuro-Oncology
Abstract:Patients with oligodendroglioma have a relatively favourable prognosis. Treatment modalities used vary, and the long-term impacts of the tumour itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of oligodendroglioma patients. In this international cross-sectional observational study, patients with oligodendroglioma (IDH-mutant and 1p/19q-codeleted) diagnosed ≥5 years ago, were recruited through the European Organisation for Research and Treatment of Cancer (EORTC) networks. Diagnosis and treatment data were collected from medical records; patients completed outcomes for HRQOL (EORTC QLQ-C30; BN20), self-reported cognitive functioning (MOS Cognitive Complaints Scale) and cognitive tests (HVLT-R, TMT, COWAT). Associations between HRQOL and cognition outcomes, and clinical variables (time since diagnosis; progression; tumour location; treatments delivered; current medication; Karnofsky Performance Status (KPS)) were explored with regression analyses. 242 oligodendroglioma patients on average 9.9 years post-diagnosis (sd=4.3, range=5.0-26.3) took part from 33 sites across 9 countries. Patients were M =52 years old (sd=12, range=23-78), the majority were men ( N =145; 60%). Higher KPS, no radiotherapy (ever), no current medication (anxiolytics/sedatives; antidepressants; dexamethasone) were associated with better generic HRQOL outcomes (QLQ-C30 functioning scale models; R 2 range 0.068-0.371, all p<.001). Higher KPS, fewer recurrences, no radiotherapy treatment (ever), and no current antidepressant use were linked to better disease-specific HRQOL (BN20 multi-item scale models; R 2 range 0.067-0.246, p<0.001). Fewer subjective cognitive complaints were associated with higher KPS and no current antipsychotic medication (R 2 =0.153, p<0.001). Better KPS, right hemispheric tumours, longer time since diagnosis, no chemotherapy (ever), no radiotherapy (ever), and no current medications (dexamethasone; antipsychotics) were predictive of better cognitive functioning (R 2 range 0.056-0.248, p<0.001). In oligodendroglioma survivors, better HRQOL and cognitive outcomes appeared consistently linked with higher KPS, no current medication use, and never having received radiotherapy. Additionally, better cognitive outcomes were associated with no chemotherapy treatment.
oncology,clinical neurology